Los Angeles Public Health announced the county would resume using Johnson & Johnson’s COVID-19 vaccine, Saturday, after the CDC and FDA lifted a nationwide “pause.”
The 11-day pause began after rare cases of blood clots were reported in 15 U.S. women under the age of 50, within two weeks of taking the single-dose Johnson & Johnson vaccine. The clots led to three deaths and seven hospitalizations out of more than 8 million doses given in the U.S.
The panel of CDC and FDA health officials concluded that the benefits of the vaccine outweighed the risks, but women under 50 should be informed about the clot risk before taking the vaccine, in case they’d like to take one of the other two.
“Vaccine providers in LA County with doses of the Janssen vaccine can resume administration of the vaccine tomorrow, provided they distribute the updated Janssen fact sheets to any recipients of the vaccine,” L.A. Public Health said in a news release Friday. “Based on their review of all available data, both the CDC and the FDA determined that the vaccine is safe and effective in preventing COVID-19.”
Vaccine providers who already have doses will be allowed to resume the Johnson & Johnson vaccinations Saturday and L.A. Public Health will provide them with an updated vaccine safety information sheet.
Advertising disclosure: We may receive compensation for some of the links in our stories. Thank you for supporting LA Weekly and our advertisers.